LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES

Translated title of the contribution: Adjuvant therapy in surgically resected colon cancer

S. Rea, F. Recchia, L. Belli, L. Jaffrain-Rea, M. L. Frati

Research output: Contribution to journalArticle

Abstract

The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.

Original languageFrench
Pages (from-to)336-342
Number of pages7
JournalSemaine des Hopitaux
Volume68
Issue number12
Publication statusPublished - 1992

Fingerprint

Colonic Neoplasms
Neoplasm Metastasis
Fluorouracil
Levamisole
Liver
Adjuvant Chemotherapy
Neoplasms
Therapeutics
Recurrence
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rea, S., Recchia, F., Belli, L., Jaffrain-Rea, L., & Frati, M. L. (1992). LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES. Semaine des Hopitaux, 68(12), 336-342.

LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES. / Rea, S.; Recchia, F.; Belli, L.; Jaffrain-Rea, L.; Frati, M. L.

In: Semaine des Hopitaux, Vol. 68, No. 12, 1992, p. 336-342.

Research output: Contribution to journalArticle

Rea, S, Recchia, F, Belli, L, Jaffrain-Rea, L & Frati, ML 1992, 'LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES', Semaine des Hopitaux, vol. 68, no. 12, pp. 336-342.
Rea S, Recchia F, Belli L, Jaffrain-Rea L, Frati ML. LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES. Semaine des Hopitaux. 1992;68(12):336-342.
Rea, S. ; Recchia, F. ; Belli, L. ; Jaffrain-Rea, L. ; Frati, M. L. / LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES. In: Semaine des Hopitaux. 1992 ; Vol. 68, No. 12. pp. 336-342.
@article{65e182b1e3254352a3a2f59ae8ad1c09,
title = "LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES",
abstract = "The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.",
author = "S. Rea and F. Recchia and L. Belli and L. Jaffrain-Rea and Frati, {M. L.}",
year = "1992",
language = "Francese",
volume = "68",
pages = "336--342",
journal = "Semaine des Hopitaux",
issn = "0037-1777",
publisher = "Expansion Scientifique Francaise",
number = "12",

}

TY - JOUR

T1 - LE TRAITEMENT ADJUVANT DES ADENOCARCINOMES COLIQUES OPERES

AU - Rea, S.

AU - Recchia, F.

AU - Belli, L.

AU - Jaffrain-Rea, L.

AU - Frati, M. L.

PY - 1992

Y1 - 1992

N2 - The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.

AB - The prognosis of colon cancer, after curative resection, is mainly related to the occurrence of metastases, and especially of liver metastases. It is generally accepted that adjuvant medical therapy is important in order to prevent the incidence of metastatic recurrences. The aim of the present review is to analyse the conclusions of the main recent randomized trials assessing the comparative value of different adjuvant protocols. The results obtained using either conventional systemic infusion or intraportal infusion, which is mainly designed to prevent liver metastases, are reported. On the basis of this review, we can conclude that: adjuvant chemotherapy using combined drugs (MF, MOF) did not prove more active than 5-FU alone. The beneficial action of a combined 5-FU + levamisole regimen was clearly demonstrated for patients with a Dukes C tumour. According to a unique and limited trial, intra-portal adjuvant therapy has been shown to be effective for patients with Dukes B tumours, but this remains to be confirmed, even though more recently four reports have been published on these experiences. On the basis of the present data, new adjuvant programs using combined chemotherapeutic and immunotherapeutic compounds, and combined systemic and loco-regional infusion, could be developped.

UR - http://www.scopus.com/inward/record.url?scp=0026579165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026579165&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0026579165

VL - 68

SP - 336

EP - 342

JO - Semaine des Hopitaux

JF - Semaine des Hopitaux

SN - 0037-1777

IS - 12

ER -